World Pneumonia Day

Pneumonia is the single largest infectious cause of death in children worldwide, but it also causes mild to life-threatening illness in people of all ages. (1)
START

How can you help improve the use of antibiotics in severe pneumonia infections?

International guidelines for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP/VAP) patients recommend broad-spectrum empiric antimicrobial therapy in high-risk patients. (2)

An earlier and broader identification of causative pathogens has the potential to reduce unnecessary antimicrobial exposure in HAP and VAP patients. In the presentations below, two experienced ICU physicians lay out how they use the BioFire Pneumonia plus panel to optimize antimicrobial therapy in their patients.

WATCH THE VIDEO

Meet The Presenters

  • 1635166404-40f17e500efee362
    Pr Pierre-François Laterre (MD)
    Head of the medical-surgical intensive care unit at Saint Luc University Hospital at the Université Catholique de Louvain, Brussels, Belgium
    In this presentation, Pr Pierre-Francois Laterre briefly reviews current practice for the antimicrobial treatment of hospitalised pneumonia patients. He points to the need to further reduce antibiotic use in HAP and VAP patients by moving from empirical to early document antibiotic therapy. Pr Laterre illustrates how and for which patients he uses the BioFire Pneumonia plus Panel. A particular focus is made on COVID-19 patients, for whom a sparse use of empiric antibiotics is key due to a high probability of the patients to develop VAP during their ICU stay. This presentation was part of BioMérieux's Industry Symposium at ECCMID 2021.
  • 1635166611-c768845f74d988c6
    Jean-Marc Tadié (MD, PhD)
    Department of Infectious Diseases and Intensive Care, University Hospital Rennes, France
    In this presentation, Pr Jean-Marc Tadié lays out how the BioFire Pneumonia plus Panel integrates into the diagnostic workflow in ICU patients with severe pneumonia.

    Using 6 clinical cases, Pr Tadié illustrates the strengths and limitations of the Panel, and how using the Panel supported both an early adjustment of the antimicrobial therapy in HAP / VAP patients and the differential diagnosis in COVID-19 patients.
WEBINARS
  • 1635508124-8725ec9de53d62b3
    In this presentation, Pr Pierre-Franc...
    Moving from empirical to early documented antibiotic therapy in ICU patients with pneumonia’
    In this presentation, Pr Pierre-Francois Laterre briefly reviews current practice for the antimicrobial treatment of hospitalised pne... View more
  • 1635497879-f81a5e9567bf0b59
    BioFire Pneumonia plus Panel: Impact on patient care
    In this presentation, Pr Jean-Marc Tadié lays out how the BioFire Pneumonia plus Panel integrates into the diagnostic workflow in ICU... View more

Learn more about the use of the BioFire Pneumonia plus Panel in the ICU

START SESSIONS
Ead-messages-offsite-icon-1